DriftingAs we look back on 2022 I can only describe it as painful and disappointing We started the year at $.26 with promise of the Dermal Injector receiving FDA Approval and and a positve conclusion to the Shiseido Arbitration. Neither of these events happened and as a result we close out the year with this disturbing share price.
We will be closing the Private Placement at the end of this month and hopefully it will be fully subscribed with the much needed operating capital to ride out the 2 big events coming in 2023:
The Dermal Injector is in the final testing stage and as per the Corporate Update will be submitted for FDA Approval in the first 3 months of the year. Secondly we know that the Hearing for the Shiseido Arbitration is on May 29th. What is an Arbitration hearing ? By definition:
"During an arbitration “hearing,” the arbitrator will listen as the parties present evidence, may ask questions of the parties and their witnesses, and may schedule more time for a party to submit evidence that the arbitrator thinks is necessary to prove or disprove a claim."
This is the last step before the Arbitrator renders a judgement. One way or another this lengthy process will come to a conclusion. The Arbitrator has up to 60 days to render this judgement after the Hearing.
In 2023 we will finally see what Replicel will be moving forward. It won't be yet another year where shareholders think something good is going to happen but never does. If all goes well with these 2 events the long suffering shareholders will finally see some sort of return on their investment. What that return will be is up for debate. Any return on investment will be welcomed at this point.